Bibliografía del artículo
1. Harreiter J, Roden M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention. WienKlinWochenschr 135(suppl1):7-17, 2023.
2. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, et al. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 46(suppl 1):19-40, 2023.
3. Chiquete J, Nuño P, Panduro A. Perspectiva histórica de la diabetes mellitus: comprendiendo la enfermedad. InvestigaciónenSalud 3:5-10, 2001.
4. Widnell C, Tata J. A procedure for the isolation of enzymically active rat-liver nuclei.Biochem J 92(2):313-317, 1964.
5. González-Mujica F. Glucosa-6-fosfatasa de envoltura nuclear de hígado de ratas. InvestClínica 49(2):169-180, 2008.
6. Foster J, Nordlie R. The biochemistry and molecular biology of the glucose-6-phosphatase system.E Biol Med 227(8)601-608, 2002.
7. Bocanegra A, Macho González A, Garcimartín A, Bendi J, Sánchez-Muniz F. Whole alga, algal extracts, and compounds as ingredients of functional foods: composition and action mechanism relationships in the prevention and treatment of type-2 diabetes mellitus. Int J MolSci 22(8):3816, 2021.
8. Sun Z, Chen F. Evaluation of the green alga Chlorella pyrenoidosa for management of diabetes. J Food Drug Anal 20(suppl 1):246-249, 2012.
9. Lauritano C, Ianora A. Marine organisms with anti-diabetes properties. Mar Drugs 14(12):220, 2016.
10. Qudus B, Aroyehun A, Abdul Razak S, Palaniveloo K, Nagappan T, et al. Bioprospecting cultivated tropical green algae, Caulerparacemosa (Forsskal) J. Agardh. A perspective on nutritional properties, antioxidative capacity and anti-diabetic potential. Foods 9(9):1313, 2020.
11. Dissanayake IH, Bandaranayake U, Keerthirathna LR, Manawadu C, Silva RM, et al. Integration of in vitro and in-silico analysis of Caulerparacemosa against antioxidant, antidiabetic, and anticancer activities. Sci Rep 12(1):20848, 2022.
12. Permatasari HK, Nurkolis F, Hardinsyah H, Taslim NA, Sabrina N, et al. Metabolomic assay, computational screening, and pharmacological evaluation of Caulerparacemosa as an anti-obesity with anti-aging by altering lipid profile and peroxisome proliferator-activated receptor-B3; coactivator 1-B1; Levels. Front Nutr 9:939073, 2022.
13. Marcucci O, González-Mujica F, Perez-Ayuso E. Alterations of liver nuclear envelopes accompanying thioacetamide administration in rats. Acta CientVenez 34(2):109-117, 1983.
14. González-Mujica F, Motta N. Actividad antihiperglicemiante de Bauhiniamegalandra. Vitae 43, 2010.
15. Burchell A, Hume R, Burchell B. A new microtechnique for the analysis of the human hepatic microsomal glucose-6-phosphatase system.ClinChimActa 173(2):183-192, 1988
16. Taussky HH, Shorr E, Kurzmann G. A microcolorimetric method for the determination of inorganic phosphorus. J BiolChem 202(11):675-685, 1953.
17. Arion WJ, Schulz LO, Lange AJ, Telford JN, Walls HE. The characteristics of liver glucose-6-phosphatase in the envelope of isolated nuclei and microsomes are identical. J BiolChem 258(9):12661-12669, 1983.
18. Igarashi Y, Kato S, Narisawa K, Tada K, Amano Y, et al. A direct evidence for defect in glucose-6-phosphate transport system in hepatic microsomal membrane of glycogen storage disease type IB. BiochemBiophys Res Commun 119(2):593-597, 1984.
19. Westergaard N, Madsen P, Lundbeck JM, Jakobsen P, Varming A, Andersen B. Identification of two novel and potent competitive inhibitors of the glucose-6-phosphatase catalytic protein. Diabetes ObesMetab 4(2):96-105, 2002.
20. Singh J, Nordlie RC, Jorgenson RA. Vanadate: a potent inhibitor of multifunctional glucose-6-phosphatase. BiochimBiophys Acta 678(3):477-482, 1981.